BioCentury
ARTICLE | Company News

Newron, Zambon Co. S.p.A sales and marketing update

July 13, 2015 7:00 AM UTC

Zambon launched Xadago safinamide in Germany to treat mid- to late-stage Parkinson’s disease (PD). Zambon has rights to Xadago in the territory from Newron. The alpha-aminoamide derivative acts as a ...